Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in ophthalmology will be read downstream.
Ophthalmology
ICG works across ophthalmology environments where durability, administration, imaging, device configuration, specialist workflow, access, and competitive sequencing must be read together.
The work includes ophthalmology competitive intelligence, retinal therapy development, biosimilar and generic entry, prefilled-syringe and delivery systems, glaucoma markets, imaging workflows, launch, and longitudinal monitoring.
The Treatment Is Part of a Clinical System.
Ophthalmology decisions cross molecule, dose interval, administration device, imaging, specialist workflow, site economics, reimbursement, and patient persistence.
ICG reconstructs how those elements combine to shape clinical confidence, switching behavior, launch readiness, and the operating position of therapies and platforms.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across ophthalmology.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Clinical-Development and Regulatory Assessment of Long-Acting Retinal Therapies
- Clinical and Commercial Assessment of Gene Therapies in Wet Age-Related Macular Degeneration
- Competitive Assessment of High-Dose Anti-VEGF Therapies in Retinal Disease
- Clinical-Positioning Assessment for Therapies in Thyroid Eye Disease
Regulatory, Access & Adoption
- Market-Access and Uptake Architecture for Retinal Therapies in Europe
- Reimbursement and Switching Assessment for Ophthalmic Biosimilars
- Access and Treatment-Pathway Assessment for Glaucoma Therapies in China
- Specialist Adoption of Sustained-Delivery Therapies in Retinal Disease
Launch & Commercial Architecture
- Prefilled-Syringe, Manufacturing and Commercial Architecture for a Leading Retinal Therapy
- Market and Device Landscape for Glaucoma Therapies in China
- Launch and Distribution Assessment for Ophthalmic Therapies in the United States and Europe
- Commercial Architecture for a Therapy in Thyroid Eye Disease in Germany and the United Kingdom
Manufacturing, Delivery & Systems
- Prefilled-Syringe and Packaging Architecture for High-Dose Retinal Therapies
- Ophthalmic Imaging Platform and Workflow Assessment Across Retinal Diseases
- AI-Enabled Retinal Imaging and Clinical-Workflow Architecture in Ophthalmology
Longitudinal Monitoring & Portfolio
- Longitudinal Generic-Entry Monitoring for a Leading Dry-Eye Therapy in the United States
- Competitive Monitoring of Retinal-Therapy Biosimilars and Delivery Systems
- Longitudinal Monitoring Across Glaucoma, Dry-Eye and Retinal Portfolios
Ophthalmology Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.